ライフサイエンスコーパス: clinical activity

1 aseline and 6 months or when patients showed clinical activity.

2 T-cell activation, uniquely correlated with clinical activity.

3 ared between groups by anatomic location and clinical activity.

4 an additional explanation for abiraterone's clinical activity.

5 okinetics, pharmacodynamics, and preliminary clinical activity.

6 ic inhibitors targeting this axis have shown clinical activity.

7 in expression were detected in patients with clinical activity.

8 uired to translate preclinical efficacy into clinical activity.

9 uggests that this cytokine may have superior clinical activity.

10 luence often representative of scholarly and clinical activity.

11 ve health-care resources without sacrificing clinical activity.

12 or, to cetuximab has shown encouraging early clinical activity.

13 s, appears to be the basis for this striking clinical activity.

14 ulated based on each scholarly (K-index) and clinical activity.

15 o correlate tumor molecular alterations with clinical activity.

16 tastatic melanoma has resulted in impressive clinical activity.

17 echanism of drug action that can explain its clinical activity.

18 pies that target this axis have demonstrated clinical activity.

19 important predictor of future endoscopic and clinical activity.

20 ited by present techniques for assessment of clinical activity.

21 w inhibitors of BCR signaling appear to have clinical activity.

22 VDAC and that this may play a role in their clinical activity.

23 acitidine is well tolerated with encouraging clinical activity.

24 enactment of a series of steps to perform a clinical activity.

25 une disease, and others show promising early clinical activity.

26 titration scheme is feasible and has robust clinical activity.

27 pear to have relatively modest scholarly and clinical activity.

28 tolerated dose (MTD), pharmacokinetics, and clinical activity.

29 and how disparity relates to differences in clinical activity.

30 cial media influence and their scholarly and clinical activity.

31 e of FcgammaRIIIA-mediated mechanisms in RTX clinical activity.

32 overall survival (OS), and PD-L1-associated clinical activity.

33 cell receptor, and a tumor target have shown clinical activity.

34 es; secondary objectives included effects on clinical activity.

35 ifiers reported actual provision of specific clinical activities.

36 ht call, but subsequent calls may compromise clinical activities.

37 Platinum compounds display clinical activity against a wide variety of solid tumors

38 bumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma i

39 ed extended persistence that correlated with clinical activity against antigen-positive myeloma.

40 differentiated in vitro has shown promising clinical activity against cancer.

41 ntly, CDK4/6 inhibitors have shown promising clinical activity against several cancer types, includin

42 ISAV was well tolerated and demonstrated clinical activity against these endemic fungi with a saf

43 our with indolent lymphomas) had evidence of clinical activity, albeit not meeting objective response

44 Safety and clinical activity analyses were reported for all patient

45 ts were expected to attend 64 activities (26 clinical activities and 38 tutorial-based activities) bu

46 ogram directors, which demonstrate ranges of clinical activities and identify significant interest fo

47 the use of polypills in future research and clinical activities and to synthesise contemporary evide

48 ese results demonstrate potential meaningful clinical activity and a manageable safety profile of isa

49 e Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety pr

50 In summary, duvelisib demonstrated promising clinical activity and an acceptable safety profile in re

51 treated with sorafenib, but did demonstrate clinical activity and an acceptable safety profile.

52 tive CD activity received CD-TREAT and their clinical activity and calprotectin were evaluated after

53 Little is known about their clinical activity and collections.

54 im analysis show that venetoclax has durable clinical activity and favourable tolerability in patient

55 Brigatinib shows promising clinical activity and has an acceptable safety profile i

56 otubule inhibitor that by itself has limited clinical activity and high systemic toxicity.

57 ary end points were safety and tolerability; clinical activity and immune activation were secondary e

58 odds ratio [OR], 0.33; 95% CI, 0.15-0.70 for clinical activity and OR, 0.35; 95% CI, 0.15-0.79 for ra

59 ronment may enhance natural killer (NK) cell clinical activity and produce encouraging results in the

60 Clinical activity and safety of brentuximab vedotin, a C

61 In this study, we report the clinical activity and safety of tazemetostat, an oral se

62 ruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancie

63 (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials.

64 ched to the antibody are key determinants of clinical activity and tolerability.

65 bstrate specificity that likely underlie the clinical activity and toxicities of each drug.

66 Our findings support the utility of initial clinical activity and treatment response by 4 weeks to p

67 Oral neratinib showed substantial clinical activity and was reasonably well tolerated amon

68 Alectinib showed clinical activity and was well tolerated in patients wit

69 ositive predictive value of 67% (4 of 6) for clinical activity, and a negative predictive value of 86

70 Periodontal disease (PD) status, clinical activity, and sociodemographic factors were det

71 Dacomitinib had encouraging clinical activity as initial systemic treatment in clini

72 HD lenalidomide has evidence of clinical activity as initial therapy for older AML patie

73 Despite there being little evidence of clinical activity as single-agent therapies, we show tha

74 tylase inhibitor romidepsin has single agent clinical activity associated with durable responses in p

75 These scientific and clinical activities, attempting to exploit the innate an

76 ncer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regard

77 erable safety profile and showed encouraging clinical activity characterised by a high response rate

78 erable safety profile and showed encouraging clinical activity characterised by a high response rate

79 P-CAP showed promising clinical activity compared with CAP in previously treate

80 Evidence of clinical activity (conventional, unconfirmed, or immune-

81 inhibitors which were found to have limited clinical activity due to insufficient kinase inhibitory

82 We recently reported promising clinical activity for a 10-day regimen of decitabine in

83 Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies,

84 Closer supervision of residents' clinical activities has been promoted to improve patient

85 Their clinical activity has been correlated with activated T-c

86 Limited clinical activity has been seen in osteosarcoma (OS) pat

87 Clinical activity has been shown by T cells bearing rece

88 olled phase II study was performed assessing clinical activity, immunologic response, and safety foll

89 f leiomyomas as well as to review the actual clinical activities in this field including efficacy and

90 s of PARP1 inhibitors (PARPi) underlie their clinical activities in various BRCA-mutated tumors.

91 of 11 evaluable subjects but correlated with clinical activity in 4.

92 th mild, reversible toxicity and substantial clinical activity in a heavily pretreated population.

93 factor receptor alpha, RET, and KIT, showed clinical activity in a phase 2 study involving patients

94 s a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elder

95 has been combined with AZA with significant clinical activity in a previous phase I dose finding stu

96 ly PCI-32765) has recently shown encouraging clinical activity in a range of lymphoid malignancies.

97 y overcome resistance and result in relevant clinical activity in a relapsed/refractory setting.

98 ether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL).

99 inhibition, providing an explanation for its clinical activity in bone marrow failure, despite alread

100 e vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic CRC,

101 potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive melanoma tumou

102 Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC.

103 Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhib

104 date, CDK4/6 inhibitors have shown promising clinical activity in breast cancer and lymphomas, but it

105 administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting

106 Immunotherapy has clinical activity in certain virally associated cancers.

107 3Kdelta-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and in

108 a selective inhibitor of PI3Kdelta, displays clinical activity in CLL, causing rapid lymph node shrin

109 , CNS-active, ALK inhibitor-showed promising clinical activity in crizotinib-naive and crizotinib-res

110 r immunotherapy has demonstrated significant clinical activity in different cancers.

111 They have also shown promising clinical activity in early-phase clinical studies and ap

112 n important target, and mTOR inhibitors show clinical activity in endometrial cancer.

113 Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC).

114 2385 demonstrated promising proof of concept clinical activity in heavily pretreated advanced ccRCC p

115 echanism-based target modulation and limited clinical activity in heavily pretreated patients with CL

116 Trastuzumab duocarmazine shows notable clinical activity in heavily pretreated patients with HE

117 ated in children and young adults and showed clinical activity in lymphoma.

118 Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary

119 ) inhibitor ibrutinib demonstrated important clinical activity in MCL.

120 Cabozantinib has clinical activity in men with CRPC, including reduction

121 2, BRD3, BRD4 and BRDt have displayed modest clinical activity in monotherapy cancer trials.

122 ar endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types.

123 Preliminary clinical activity in newly diagnosed diffuse large B-cel

124 fic inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic ly

125 MEK inhibitors, which have shown clinical activity in NRAS-mutant melanoma, may be effect

126 ibitor veliparib (ABT-888), four agents with clinical activity in ovarian cancer.

127 a covalent pan-HER inhibitor that has shown clinical activity in patients previously treated with ge

128 peutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma.

129 Lorlatinib showed clinical activity in patients with advanced ROS1-positiv

130 ituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL.

131 le-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC

132 -199 (venetoclax) has demonstrated promising clinical activity in patients with chronic lymphocytic l

133 nase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic l

134 Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic l

135 ive, and potent ALK inhibitor that has shown clinical activity in patients with crizotinib-naive ALK-

136 demonstrated that inhibitors of FLT3 do have clinical activity in patients with FLT3-mutant AML, alth

137 Cabozantinib has single-agent clinical activity in patients with heavily pretreated, p

138 inase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metasta

139 Dasatinib has significant clinical activity in patients with imatinib resistance.

140 s bioavailable and demonstrated biologic and clinical activity in patients with MDSs and CMML.

141 nged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid can

142 tic index and RAF inhibitors have remarkable clinical activity in patients with melanomas that harbou

143 ression is well-tolerated and shows signs of clinical activity in patients with mesothelioma.

144 lymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer.

145 Pazopanib has clinical activity in patients with progressive desmoid t

146 recently has been shown to have significant clinical activity in patients with relapsed Hodgkin lymp

147 IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractor

148 Quizartinib has clinical activity in patients with relapsed/refractory A

149 nation of cixutumumab and temsirolimus shows clinical activity in patients with sarcoma and forms a b

150 le safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, m

151 The drug seems to mediate some clinical activity in pediatric solid tumors and may work

152 CD19 BiTE((R)) blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)-negati

153 SRC/ABL tyrosine kinase inhibitor (TKI) with clinical activity in Philadelphia chromosome-positive (P

154 with AZA, and this combination demonstrates clinical activity in relapsed AML/MDS without reversing

155 d T cells that express CARs, with impressive clinical activity in relapsed and refractory hematologic

156 E3 ubiquitin ligase modulator, demonstrated clinical activity in relapsed/refractory DLBCL patients,

157 ori, PF-02341066) has demonstrated promising clinical activity in ROS1 fusion-positive non-small cell

158 hows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC.

159 se drugs were already being tested for their clinical activity in schizophrenia and other neuropsychi

160 he shortlisted drugs, have also demonstrated clinical activity in schizophrenia and other related dis

161 mab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patien

162 de (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC).

163 However, clinical activity in solid tumors has been disappointing

164 versible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and

165 -3-kinase (PI3K)-alpha inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of

166 Entospletinib demonstrates clinical activity in subjects with relapsed or refractor

167 ptosis of ATL cell lines and has significant clinical activity in Tax-driven murine ATL or human pati

168 y indicated that FR104 has potential to show clinical activity in the treatment of immune-mediated di

169 mTOR inhibitors have shown major clinical activity in the treatment of renal cell carcino

170 s in reducing magnetic resonance imaging and clinical activity in therapeutic trials indicates that B

171 Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanc

172 A phase II trial was performed to determine clinical activity in this patient cohort.

173 Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF

174 is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-res

175 We recorded some evidence of clinical activity in various solid tumours, with partial

176 ther improved CD20 antibodies with promising clinical activity, including ofatumumab and GA-101, are

177 d B-cell lymphoma and demonstrates promising clinical activity, including patients who were refractor

178 High clinical activity indices (CAI) and sigmoidoscopy scores

179 Clinical coding is the translation of clinical activity into a coded language.

180 ical development and despite promising early clinical activity, intrinsic resistance is frequent amon

181 The ability to predict future clinical activity is uncertain, likely limited by presen

182 squinimod and offer a perspective on how its clinical activity might be leveraged in combination with

183 Purpose The clinical activity observed in a phase I dose-escalation

184 The degree of clinical activity observed supports additional studies t

185 eatment of nonpromyelocytic AML with limited clinical activity observed.

186 Prior work showed immunologic and clinical activity of 6MHP alone.

187 These results are the first to establish the clinical activity of a CD22-CAR in B-ALL, including leuk

188 safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody-dr

189 he objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humaniz

190 jective of this study is to evaluate the pre-clinical activity of ATR inhibition in soft tissue sarco

191 e 1 dose-expansion study assessed safety and clinical activity of avadomide monotherapy in patients w

192 ) and objective response rate suggested some clinical activity of bevacizumab and erlotinib.

193 oantigens appears an important driver of the clinical activity of both T cell checkpoint blockade and

194 These data provide an explanation for the clinical activity of CAL-101, and a roadmap for future t

195 irculating and image-derived biomarkers, and clinical activity of combination aflibercept and docetax

196 Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK

197 -arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAF(V600E/K) mutatio

198 We did a trial to assess the clinical activity of dabrafenib in patients with advance

199 demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML a

200 l evidence, including the lack of convincing clinical activity of early FLT3 inhibitors, suggests tha

201 ic and pharmacodynamic profiles, safety, and clinical activity of enasidenib in patients with mutant-

202 The clinical activity of fibroblast growth factor receptor (

203 olecular mechanism underlying the intriguing clinical activity of HMAs in AML/MDS patients with chrom

204 Considering the disappointing clinical activity of HSP90 inhibitors in other contexts,

205 provides additional evidence for the durable clinical activity of immune checkpoint inhibitors in the

206 im of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy

207 redictive value of beta3T in differentiating clinical activity of ixabepilone- or paclitaxel-containi

208 s concept recently gained momentum after the clinical activity of kinase inhibitors that target BCR s

209 These findings have implications for the clinical activity of lenalidomide and related compounds,

210 ansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853)

211 However, the clinical activity of NAMPT inhibitors has proven limited

212 te safety, pharmacokinetics, and preliminary clinical activity of OTX015.

213 Clinical activity of PARP inhibitors (PARPis) in BRCA1/2

214 This is the first demonstration of clinical activity of PD-1 blockade in DLBCL.

215 enrolled in a phase II study to evaluate the clinical activity of pembrolizumab 200 mg every 3 weeks,

216 We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti-programmed d

217 We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or

218 s could be a new way to detect a significant clinical activity of proteasome inhibitors in AML patien

219 Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RI

220 the biodistribution, dosimetry, safety, and clinical activity of radretumab.

221 ective exploratory analysis investigated the clinical activity of regorafenib in biomarker subgroups

222 se 2 dose, pharmacokinetics, and preliminary clinical activity of rogaratinib.

223 The clinical activity of sirolimus in PEComa additionally st

224 The impressive clinical activity of small-molecule receptor tyrosine ki

225 We aimed to assess the safety and clinical activity of subcutaneously given guadecitabine

226 r (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood.

227 lon inhibitor, which may in part explain the clinical activity of TGR-1202 in aggressive lymphoma not

228 of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chr

229 We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prexaser

230 of this study was to explore the safety and clinical activity of the combination of brentuximab vedo

231 the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentux

232 The clinical activity of these newer investigational therapi

233 This study demonstrates the tolerability and clinical activity of this combination with quicker time

234 ssibly explaining some of the characteristic clinical activity of this new targeted agent.

235 We report herein on the preclinical and clinical activity of this targeted strategy in aggressiv

236 Our data show substantial clinical activity of trametinib in melanoma and suggest

237 Nonetheless, the clinical activity of various chemotherapies is now known

238 accines, with a focus on the preclinical and clinical activities on the MV/Schw-based candidate, whic

239 stoma, although cediranib showed evidence of clinical activity on some secondary end points including

240 ut do not have any relevance with respect to clinical activity or prognosis.

241 ed by considerable favorable preclinical and clinical activities over the past several years and culm

242 lt, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents.

243 CCR4, is well tolerated and has significant clinical activity (overall response rate 36.8%, median d

244 The observed clinical activity (partial response and prolonged progre

245 Among biomarkers to assess clinical activity, pentraxin-3 is perhaps the most promi

246 and toxicity; secondary end points assessed clinical activity per Response Evaluation Criteria in So

247 lung cancer (NSCLC) by the FDA, demonstrates clinical activity primarily in patients with tumors that

248 The observed safety/tolerability and clinical activity profile of sifalimumab support its con

249 If clinical activity recurred or persisted, the interval be

250 cted by comparing men and women with similar clinical activity, renumeration was still lower for wome

251 She received 4/7 points in the Clinical Activity Scale (CAS) and class IV in the NO SPE

252 ogic correlation was made by determining the clinical activity score (CAS) of each patient with TED.

253 ands were calculated and correlated with the clinical activity score (CAS).

254 sease assessment include the Indian Takayasu Clinical Activity Score (ITAS2010), which incorporates c

255 ed as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with

256 response (78% of patients [32] vs. 7% [3]), Clinical Activity Score of 0 or 1 (59% [24] vs. 21% [9])

257 plus a reduction in proptosis of >=2 mm), a Clinical Activity Score of 0 or 1 (indicating no or mini

258 l response (a reduction of >=2 points in the Clinical Activity Score plus a reduction in proptosis of

259 te, symptomatic Graves' ophthalmopathy (mean clinical activity score, 6.2) but no optic neuropathy, d

260 ontinuous variables, included proptosis, the Clinical Activity Score, and results on the Graves' opht

261 n better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life t

262 e than placebo in reducing proptosis and the Clinical Activity Score.

263 Its clinical activity should be further assessed in NHL.

264 Its impressive clinical activity shown in a phase IB trial led to accel

265 Early evidence of clinical activity shows promise for PT2977 in the treatm

266 No statistically significant differences in clinical activity (SLEDAI and British Isles Lupus Assess

267 performing basic science research alongside clinical activity - so-called surgeon scientists.

268 ce, with equity in opportunity and parity in clinical activity standing to benefit the specialty.

269 k proposes epigenetic discrimination between clinical activity states, and reveals T-cell-related bio

270 clinical results, along with early promising clinical activity, suggest that CC-115 may be developed

271 -brain barrier by AZD3759, and its promising clinical activity, support further assessment of this co

272 We report clinical activity, survival, and long-term safety in pat

273 had a manageable safety profile and provided clinical activity that appears to be distinct from that

274 ls were increased by 2 weeks if there was no clinical activity, to a maximum of 12 weeks.

275 inib's inhibition of the expected target and clinical activity warrants its further development as a

276 Clinical activity was assessed before and four weeks fol

277 Clinical activity was assessed by the Rachmilewitz Index

278 to trastuzumab, the safety was improved and clinical activity was demonstrated.

279 In the MAGE-A3+AS15 arm, clinical activity was higher and the immune response mor

280 Evidence of clinical activity was noted both in patients with PD-L1-

281 Some suggestion of clinical activity was noted in 23 (49%) of 47 patients w

282 ab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pa

283 Minimal clinical activity was observed as sequential therapy in

284 Significant clinical activity was observed in BRAF-inhibitor-naive p

285 oup of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-pro

286 Clinical activity was observed independent of PIK3CA mut

287 Otlertuzumab was well tolerated, and modest clinical activity was observed.

288 Safety and clinical activity were assessed in all patients who rece

289 ous and current therapy, laboratory data and clinical activity were recorded at the time of TDM.

290 Pathway inhibition and clinical activity were seen, with 21 (10%) objective res

291 IK3CA/PIK3R1 mutation did not correlate with clinical activity, whereas RAS/RAF pathway mutations did

292 The findings of clinical activity will require validation in a phase 2 t

293 Axitinib shows clinical activity with a manageable safety profile in tr

294 chieves early steady-state concentration and clinical activity with an acceptable safety profile in r

295 nal chemotherapy, our finding of significant clinical activity with cediranib in this disease is an i

296 herapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse

297 Osimertinib showed clinical activity with manageable side-effects in patien

298 e times per week, has promising single-agent clinical activity with manageable toxicity in patients w

299 Despite measurable clinical activity with new targeted therapies, many pati

300 Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in